Previous 10 | Next 10 |
Athersys (NASDAQ: ATHX ): Q3 GAAP EPS of -$0.08 beats by $0.01 . Cash and equivalents of $40.4M. Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news, ,
CLEVELAND, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2019. Highlights of the third quarter of 2019 and recent events include: Steady advancement of both MultiStem ® ischemic...
CLEVELAND, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the res...
Every week, Seeking Alpha PRO+ Small and Micro provides subscribers with an exclusive roundup of must-read small- and microcap coverage on many underfollowed stocks. This week, we are making the newsletter available to all readers. To learn more about PRO+, please click here . Technol...
CLEVELAND, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2 nd -4 th in Carlsbad, California. Dr. Van Bokkelen will provide a ...
On June 14, 2019, I published " The Stem Cell Triple Play: 3 Companies With Great Value Drivers ". Given how out of favor the stem cell sector has been for many years, I was surprised by the massive interest that this article generated. Given this unexpected level of interest and some co...
Company Overview I will be brief in the company overview since you can get a much more detailed breakdown of Athersys ( ATHX ) research strategy at their website , but they are developing drugs to treat various conditions that have little or no other treatment alternatives by using their pr...
Arcadia Biosciences (NASDAQ: RKDA ) +21% on high fiber wheat deal . More news on: Arcadia Biosciences, Inc., The Medicines Company, Pitney Bowes Inc., Stocks on the move, Read more ...
The following slide deck was published by Athersys, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Athersys, Inc. (ATHX) Q2 2019 Earnings Conference Call August 07, 2019, 16:30 ET Company Participants Karen Hunady - Director, Corporate Communications & IR Laura Campbell - SVP, Finance William Lehmann - President, COO & Secretary Conference Call Participants Jason...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...